These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21187728)

  • 21. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
    Ridker PM; Rifai N; Rose L; Buring JE; Cook NR
    N Engl J Med; 2002 Nov; 347(20):1557-65. PubMed ID: 12432042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein is an essential aspect of cardiovascular risk factor stratification.
    Yeh ET
    Can J Cardiol; 2004 Aug; 20 Suppl B():93B-96B. PubMed ID: 15309212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should we measure CRP levels to assess cardiovascular risk?
    Hadley RD; Graber MA
    JAAPA; 2003 Jan; 16(1):17-9. PubMed ID: 12635434
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin.
    May A; Wang TJ
    Expert Rev Mol Diagn; 2007 Nov; 7(6):793-804. PubMed ID: 18020909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NASH and cardiovascular biomarkers.
    Ercin CN; Dogru T; Tasci I; Erdem G; Sonmez A; Tapan S
    Obesity (Silver Spring); 2009 Apr; 17(4):627; author reply 627. PubMed ID: 19322144
    [No Abstract]   [Full Text] [Related]  

  • 26. After menopause: novel marker helps to identify women at risk for heart disease.
    Lewis SL
    J Fam Pract; 2004 Jul; Suppl():S18-24. PubMed ID: 15251109
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prognostic value of C-reactive protein in ischemic cardiopathy].
    Bazzino O; Natale E
    Medicina (B Aires); 2001; 61(2):239-42. PubMed ID: 11374151
    [No Abstract]   [Full Text] [Related]  

  • 28. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women].
    Biasucci LM
    Ital Heart J Suppl; 2000 Aug; 1(8):1066-7. PubMed ID: 10993018
    [No Abstract]   [Full Text] [Related]  

  • 30. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.
    Lee DS; Evans JC; Robins SJ; Wilson PW; Albano I; Fox CS; Wang TJ; Benjamin EJ; D'Agostino RB; Vasan RS
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):127-33. PubMed ID: 17095717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.
    Sinning JM; Bickel C; Messow CM; Schnabel R; Lubos E; Rupprecht HJ; Espinola-Klein C; Lackner KJ; Tiret L; Münzel T; Blankenberg S;
    Eur Heart J; 2006 Dec; 27(24):2962-8. PubMed ID: 17132649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes.
    Tuomikoski P; Mikkola TS; Hämäläinen E; Tikkanen MJ; Turpeinen U; Ylikorkala O
    Menopause; 2010; 17(1):145-51. PubMed ID: 19602991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [C-reactive protein in patients with coronary heart disease].
    Rajtar R; Kolasińska-Kloch W; Kloch M
    Folia Med Cracov; 2004; 45(1-2):25-32. PubMed ID: 16276823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG; Herrington DM
    Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting cardiovascular complications after liver transplantation: 007 to the rescue?
    Liu H; Lee SS
    Liver Transpl; 2011 Jan; 17(1):7-9. PubMed ID: 21254338
    [No Abstract]   [Full Text] [Related]  

  • 38. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
    Windgassen EB; Funtowicz L; Lunsford TN; Harris LA; Mulvagh SL
    Postgrad Med; 2011 Jan; 123(1):114-9. PubMed ID: 21293091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-reactive protein in the prediction of cardiovascular disease.
    Horowitz GL; Beckwith BA
    N Engl J Med; 2000 Aug; 343(7):512-3. PubMed ID: 10950678
    [No Abstract]   [Full Text] [Related]  

  • 40. C-reactive protein and cardiovascular disease: are we looking in the right direction?
    Hashimoto J; O'Rourke MF
    J Hypertens; 2006 Oct; 24(10):2115. PubMed ID: 16957575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.